Suppr超能文献

免疫抑制蛋白及其在自身免疫和自身免疫性肝炎中的致病和治疗意义。

Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester , MN , USA.

出版信息

Autoimmunity. 2019 Jun;52(4):144-160. doi: 10.1080/08916934.2019.1641200. Epub 2019 Jul 12.

Abstract

Key inhibitory proteins can blunt immune responses to self-antigens, and deficiencies in this repertoire may promote autoimmunity. The goals of this review are to describe the key immune inhibitory proteins, indicate their possible impact on the development of autoimmune disease, especially autoimmune hepatitis, and encourage studies to clarify their pathogenic role and candidacy as therapeutic targets. English abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed. Cytotoxic T lymphocyte antigen-4 impairs ligation of CD28 to B7 ligands on antigen presenting cells and inhibits the adaptive immune response by increasing anti-inflammatory cytokines, generating regulatory T cells, and reducing T cell activation and proliferation. Programed cell death antigen-1 inhibits T cell selection, activation, and proliferation by binding with two ligands at different phases and locations of the immune response. A soluble alternatively spliced variant of this protein can dampen the inhibitory signal. Autoimmune hepatitis has been associated with polymorphisms of the cytotoxic T lymphocyte antigen-4 gene, reduced hepatic expression of a ligand of programed cell death antigen-1, an interfering soluble variant of this key inhibitory protein, and antibodies against it. Findings have been associated with laboratory indices of liver injury and suboptimal treatment response. Abatacept, belatacept, CD28 blockade, and induction of T cell exhaustion are management considerations that require scrutiny. In conclusion, deficiencies in key immune inhibitory proteins may promote the occurrence of autoimmune diseases, such as autoimmune hepatitis, and emerging interventions may overcome these deficiencies. Investigations should define the nature, impact and management of these inhibitory disturbances in autoimmune hepatitis.

摘要

关键抑制性蛋白可削弱针对自身抗原的免疫应答,而该蛋白谱的缺乏可能会促进自身免疫。本综述的目的是描述关键免疫抑制蛋白,指出它们可能对自身免疫性疾病(尤其是自身免疫性肝炎)的发展产生的影响,并鼓励开展研究以阐明其致病作用和作为治疗靶点的潜力。通过多个搜索词在 PubMed 中确定英文摘要。选择全文进行综述,并开发二级和三级参考文献。细胞毒性 T 淋巴细胞抗原-4 通过增加抗炎细胞因子、产生调节性 T 细胞以及减少 T 细胞激活和增殖,削弱 CD28 与抗原呈递细胞上 B7 配体的连接,从而抑制适应性免疫应答。程序性细胞死亡抗原-1 通过在免疫应答的不同阶段和位置与两种配体结合来抑制 T 细胞的选择、激活和增殖。该蛋白的可溶性可变剪接变体可减弱抑制信号。细胞毒性 T 淋巴细胞抗原-4 基因的多态性、程序性细胞死亡抗原-1 配体在肝脏中的表达减少、该关键抑制性蛋白的干扰性可溶性变体以及针对该蛋白的抗体与自身免疫性肝炎有关。这些发现与肝损伤的实验室指标和治疗反应不佳有关。阿巴西普、贝利尤单抗、CD28 阻断和诱导 T 细胞耗竭是需要仔细考虑的治疗方法。总之,关键免疫抑制蛋白的缺乏可能会促进自身免疫性疾病(如自身免疫性肝炎)的发生,而新出现的干预措施可能会克服这些缺陷。研究应明确这些抑制性紊乱在自身免疫性肝炎中的性质、影响和管理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验